Trius Therapeutics Receives “Outperform” Rating from Oppenheimer (TSRX)
Trius Therapeutics (NASDAQ: TSRX)‘s stock had its “outperform” rating restated by analysts at Oppenheimer in a research report issued to clients and investors on Wednesday. They currently have a $12.00 price target on the stock.
The analysts wrote, “On 3/12, TSRX reported 4Q12 EPS of ($0.36), above our ($0.54) forecast, owing to higher revenues of $5.2M (vs. our $2.9M estimate) and lower operating expenses of $21.1 (vs. our $24.2M estimate). Most important, we anticipate an imminent top-line readout, likely by the end of March, from Tedizolid’s phase III ESTABLISH-2 study and a subsequent NDA filing during 2H13 (suggesting potential approval in 1H14). We believe TSRX will initiate a Phase III study in lung infections in 2H13 (we previously expected 1H13), suggesting potential approval in the lung in ~2016. We are adjusting, estimates to reflect revised operating expense expectations.”
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated an “outperform” rating on shares of Trius Therapeutics in a research note to investors on Wednesday. They now have a $12.00 price target on the stock. Separately, analysts at Piper Jaffray reiterated an “overweight” rating on shares of Trius Therapeutics in a research note to investors on Wednesday. They now have a $11.00 price target on the stock. Finally, analysts at Aegis cut their price target on shares of Trius Therapeutics from $15.00 to $14.00 in a research note to investors on Thursday, January 24th. They now have a “buy” rating on the stock.
Seven equities research analysts have rated the stock with a buy rating, and one has issued an overweight rating to the company’s stock. The company has a consensus rating of “buy” and a consensus target price of $11.75.
Trius Therapeutics traded up 7.07% on Wednesday, hitting $6.649. Trius Therapeutics has a 52-week low of $4.41 and a 52-week high of $6.49. The stock’s 50-day moving average is currently $5.40. The company’s market cap is $262.0 million.
Trius Therapeutics, Inc. (Trius) is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for serious, life threatening infections.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.